• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Integra LifeSciences Holdings (IART) Resets Guidance As The Undervalued Narrative Faces A Fresh Test

    Simply Wall St·10/09/2026 03:38:06
    Listen to the news

    Integra LifeSciences Holdings (IART) reset expectations on 2 October, trimming its full year 2026 revenue outlook while also laying out fresh guidance for the upcoming quarter. This combination put earnings visibility in sharper focus for investors.

    The reset in guidance landed after a sharp swing in sentiment, with Integra LifeSciences Holdings’ share price down 16.66% over the past week and 28.63% over 90 days, even though its year to date share price return is 11.66%. That short term hit comes on top of a 5.30% decline in 1 year total shareholder return and a much steeper 64.65% and 80.04% drop in 3 and 5 year total shareholder returns. This points to fading momentum as investors reassess both growth prospects and risk around the story.

    Spot fresh opportunities by comparing Integra LifeSciences Holdings with a hand picked 27 high quality undervalued stocks that currently screens well on both quality and price.

    Integra LifeSciences Holdings now trades at a steep discount to both intrinsic estimates and analyst targets after the guidance cut and refinancing plans. Is that gap caution well placed, or is it starting to look overdone as valuation maths tightens?

    Most Popular Narrative: 50% Undervalued

    Integra LifeSciences Holdings closed at $13.41, while the most followed narrative anchors fair value at $27.00. The gap now hinges on whether recent fixes in the business can stick.

    Analysts already factor in Integra LifeSciences Holdings finishing its Compliance Master Plan and stabilising operations. However, the reported reduction in remediation spending, several quarters without major supply upsets and ongoing transformation savings point to further room for structural cost efficiency gains that could still lift gross margin and earnings quality beyond what current models assume.

    See why 2 investors see Integra LifeSciences Holdings as 50% undervalued.

    Result: Fair Value of $27.00 (UNDERVALUED)

    Still, if Integra LifeSciences Holdings stumbles on guidance again or struggles to reduce leverage from roughly US$1.6b, the optimistic margin recovery story could quickly fade.

    Find out about the key risks to this Integra LifeSciences Holdings narrative.

    Next Steps

    If this Integra LifeSciences Holdings narrative feels split between concern and potential, do not sit on the fence. Consider those signals carefully, starting with the 3 key rewards and 1 important warning sign.

    Looking for more Integra LifeSciences ideas and beyond?

    Integra LifeSciences Holdings may already be on your radar, but the next move often comes from comparing it with other clear, data driven opportunities.

    Use the Simply Wall St screener to pressure test your thinking and uncover fresh angles before the market prices them in.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.